+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Thrombosis Drug Market Research Report by Drug Class, Disease Type, Distribution Channel, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 148 Pages
  • October 2022
  • Region: United States
  • 360iResearch™
  • ID: 5124134
UP TO OFF until Dec 31st 2022
The United States Thrombosis Drug Market size was estimated at USD 5,277.50 million in 2021, USD 5,857.44 million in 2022, and is projected to grow at a CAGR of 7.52% to reach USD 8,157.87 million by 2027.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Thrombosis Drug to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug Class, the market was studied across Factor Xa Inhibitor, Heparin, and P2Y12 Platelet Inhibitor.
  • Based on Disease Type, the market was studied across Atrial Fibrillation, Deep Vein Thrombosis, and Pulmonary Embolism.
  • Based on Distribution Channel, the market was studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. This ongoing research amplifies This research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:

The publisher continuously monitors and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Thrombosis Drug market considering the current update on the conflict and its global response.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Thrombosis Drug Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor's strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Thrombosis Drug Market, including Aspen Pharmacare Holdings Limited, AstraZeneca PLC, AuroMedics Pharma LLC, Baxter International, Inc., Bayer AG, Biogen Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, DAIICHI SANKYO COMPANY, LIMITED., GlaxoSmithKline plc, GoodRx, Inc., Grifols, S.A, Inari Medical, Inc., ITALFARMACO S.p.A, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Mylan N.V., Pfizer, Inc, Sanofi, and Vasudha Pharma.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Thrombosis Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Thrombosis Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Thrombosis Drug Market?
4. What is the competitive strategic window for opportunities in the United States Thrombosis Drug Market?
5. What are the technology trends and regulatory frameworks in the United States Thrombosis Drug Market?
6. What is the market share of the leading vendors in the United States Thrombosis Drug Market?
7. What modes and strategic moves are considered suitable for entering the United States Thrombosis Drug Market?
Frequently Asked Questions about the U.S. Thrombosis Drug Market

What is the estimated value of the U.S. Thrombosis Drug Market?

The U.S. Thrombosis Drug Market was estimated to be valued at $5277.5 Million in 2021.

What is the growth rate of the U.S. Thrombosis Drug Market?

The growth rate of the U.S. Thrombosis Drug Market is 7.5%, with an estimated value of $8157.87 Million by 2027.

What is the forecasted size of the U.S. Thrombosis Drug Market?

The U.S. Thrombosis Drug Market is estimated to be worth $8157.87 Million by 2027.

Who are the key companies in the U.S. Thrombosis Drug Market?

Key companies in the U.S. Thrombosis Drug Market include Aspen Pharmacare Holdings Limited, AstraZeneca PLC, AuroMedics Pharma LLC, Baxter International, Inc., Bayer AG, Biogen Inc, Boehringer Ingelheim GmbH, Bristol and DAIICHI SANKYO COMPANY, LIMITED..

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Thrombosis Drug Market, by Drug Class
6.1. Introduction
6.2. Factor Xa Inhibitor
6.3. Heparin
6.4. P2Y12 Platelet Inhibitor
7. Thrombosis Drug Market, by Disease Type
7.1. Introduction
7.2. Atrial Fibrillation
7.3. Deep Vein Thrombosis
7.4. Pulmonary Embolism
8. Thrombosis Drug Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. California Thrombosis Drug Market
9.1. Introduction
10. Florida Thrombosis Drug Market
10.1. Introduction
11. Illinois Thrombosis Drug Market
11.1. Introduction
12. New York Thrombosis Drug Market
12.1. Introduction
13. Ohio Thrombosis Drug Market
13.1. Introduction
14. Pennsylvania Thrombosis Drug Market
14.1. Introduction
15. Texas Thrombosis Drug Market
15.1. Introduction
16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis, By Key Player
16.3. Market Share Analysis, By Key Player
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration, & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding
16.4.5. Award, Recognition, & Expansion
17. Company Usability Profiles
17.1. Aspen Pharmacare Holdings Limited
17.1.1. Business Overview
17.1.2. Key Executives
17.1.3. Product & Services
17.2. AstraZeneca PLC
17.2.1. Business Overview
17.2.2. Key Executives
17.2.3. Product & Services
17.3. AuroMedics Pharma LLC
17.3.1. Business Overview
17.3.2. Key Executives
17.3.3. Product & Services
17.4. Baxter International, Inc.
17.4.1. Business Overview
17.4.2. Key Executives
17.4.3. Product & Services
17.5. Bayer AG
17.5.1. Business Overview
17.5.2. Key Executives
17.5.3. Product & Services
17.6. Biogen Inc
17.6.1. Business Overview
17.6.2. Key Executives
17.6.3. Product & Services
17.7. Boehringer Ingelheim GmbH
17.7.1. Business Overview
17.7.2. Key Executives
17.7.3. Product & Services
17.8. Bristol-Myers Squibb
17.8.1. Business Overview
17.8.2. Key Executives
17.8.3. Product & Services
17.9. DAIICHI SANKYO COMPANY, LIMITED.
17.9.1. Business Overview
17.9.2. Key Executives
17.9.3. Product & Services
17.10. GlaxoSmithKline plc
17.10.1. Business Overview
17.10.2. Key Executives
17.10.3. Product & Services
17.11. GoodRx, Inc.
17.11.1. Business Overview
17.11.2. Key Executives
17.11.3. Product & Services
17.12. Grifols, S.A
17.12.1. Business Overview
17.12.2. Key Executives
17.12.3. Product & Services
17.13. Inari Medical, Inc.
17.13.1. Business Overview
17.13.2. Key Executives
17.13.3. Product & Services
17.14. ITALFARMACO S.p.A
17.14.1. Business Overview
17.14.2. Key Executives
17.14.3. Product & Services
17.15. Janssen Pharmaceuticals, Inc.
17.15.1. Business Overview
17.15.2. Key Executives
17.15.3. Product & Services
17.16. Johnson & Johnson
17.16.1. Business Overview
17.16.2. Key Executives
17.16.3. Product & Services
17.17. Mylan N.V.
17.17.1. Business Overview
17.17.2. Key Executives
17.17.3. Product & Services
17.18. Pfizer, Inc
17.18.1. Business Overview
17.18.2. Key Executives
17.18.3. Product & Services
17.19. Sanofi
17.19.1. Business Overview
17.19.2. Key Executives
17.19.3. Product & Services
17.20. Vasudha Pharma
17.20.1. Business Overview
17.20.2. Key Executives
17.20.3. Product & Services
18. Appendix
18.1. Discussion Guide
18.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES THROMBOSIS DRUG MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES THROMBOSIS DRUG MARKET SIZE, 2021 VS 2027
FIGURE 3. UNITED STATES THROMBOSIS DRUG MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 4. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 5. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 6. UNITED STATES THROMBOSIS DRUG MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2027
FIGURE 7. UNITED STATES THROMBOSIS DRUG MARKET DYNAMICS
FIGURE 8. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (%)
FIGURE 9. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (USD MILLION)
FIGURE 10. UNITED STATES THROMBOSIS DRUG MARKET COMPETITIVE STRATEGIC WINDOW, BY DRUG CLASS, 2027
FIGURE 11. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITOR, 2018-2027 (USD MILLION)
FIGURE 12. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY HEPARIN, 2018-2027 (USD MILLION)
FIGURE 13. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY P2Y12 PLATELET INHIBITOR, 2018-2027 (USD MILLION)
FIGURE 14. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2021 VS 2027 (%)
FIGURE 15. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 16. UNITED STATES THROMBOSIS DRUG MARKET COMPETITIVE STRATEGIC WINDOW, BY DISEASE TYPE, 2027
FIGURE 17. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2027 (USD MILLION)
FIGURE 18. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2027 (USD MILLION)
FIGURE 19. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2027 (USD MILLION)
FIGURE 20. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (%)
FIGURE 21. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (USD MILLION)
FIGURE 22. UNITED STATES THROMBOSIS DRUG MARKET COMPETITIVE STRATEGIC WINDOW, BY DISTRIBUTION CHANNEL, 2027
FIGURE 23. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2027 (USD MILLION)
FIGURE 24. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY ONLINE PHARMACIES, 2018-2027 (USD MILLION)
FIGURE 25. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2027 (USD MILLION)
FIGURE 26. CALIFORNIA THROMBOSIS DRUG MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 27. FLORIDA THROMBOSIS DRUG MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 28. ILLINOIS THROMBOSIS DRUG MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 29. NEW YORK THROMBOSIS DRUG MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 30. OHIO THROMBOSIS DRUG MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 31. PENNSYLVANIA THROMBOSIS DRUG MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 32. TEXAS THROMBOSIS DRUG MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 33. UNITED STATES THROMBOSIS DRUG MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 34. UNITED STATES THROMBOSIS DRUG MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 35. UNITED STATES THROMBOSIS DRUG MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2021
List of Tables
TABLE 1. UNITED STATES THROMBOSIS DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2021
TABLE 3. UNITED STATES THROMBOSIS DRUG MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 4. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY STATE, 2018-2027 (USD MILLION)
TABLE 5. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 6. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITOR, 2018-2027 (USD MILLION)
TABLE 7. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITOR, BY STATE, 2018-2027 (USD MILLION)
TABLE 8. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY HEPARIN, 2018-2027 (USD MILLION)
TABLE 9. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY HEPARIN, BY STATE, 2018-2027 (USD MILLION)
TABLE 10. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY P2Y12 PLATELET INHIBITOR, 2018-2027 (USD MILLION)
TABLE 11. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY P2Y12 PLATELET INHIBITOR, BY STATE, 2018-2027 (USD MILLION)
TABLE 12. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 13. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2027 (USD MILLION)
TABLE 14. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY ATRIAL FIBRILLATION, BY STATE, 2018-2027 (USD MILLION)
TABLE 15. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2027 (USD MILLION)
TABLE 16. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY STATE, 2018-2027 (USD MILLION)
TABLE 17. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2027 (USD MILLION)
TABLE 18. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY PULMONARY EMBOLISM, BY STATE, 2018-2027 (USD MILLION)
TABLE 19. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 20. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2027 (USD MILLION)
TABLE 21. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY STATE, 2018-2027 (USD MILLION)
TABLE 22. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY ONLINE PHARMACIES, 2018-2027 (USD MILLION)
TABLE 23. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY STATE, 2018-2027 (USD MILLION)
TABLE 24. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2027 (USD MILLION)
TABLE 25. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY STATE, 2018-2027 (USD MILLION)
TABLE 26. CALIFORNIA THROMBOSIS DRUG MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 27. CALIFORNIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 28. CALIFORNIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 29. CALIFORNIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 30. FLORIDA THROMBOSIS DRUG MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 31. FLORIDA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 32. FLORIDA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 33. FLORIDA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 34. ILLINOIS THROMBOSIS DRUG MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 35. ILLINOIS THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 36. ILLINOIS THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 37. ILLINOIS THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 38. NEW YORK THROMBOSIS DRUG MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 39. NEW YORK THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 40. NEW YORK THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 41. NEW YORK THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 42. OHIO THROMBOSIS DRUG MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 43. OHIO THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 44. OHIO THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 45. OHIO THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 46. PENNSYLVANIA THROMBOSIS DRUG MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 47. PENNSYLVANIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 48. PENNSYLVANIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 49. PENNSYLVANIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 50. TEXAS THROMBOSIS DRUG MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 51. TEXAS THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 52. TEXAS THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 53. TEXAS THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 54. UNITED STATES THROMBOSIS DRUG MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 55. UNITED STATES THROMBOSIS DRUG MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 56. UNITED STATES THROMBOSIS DRUG MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 57. UNITED STATES THROMBOSIS DRUG MARKET RANKING, BY KEY PLAYER, 2021
TABLE 58. UNITED STATES THROMBOSIS DRUG MARKET SHARE, BY KEY PLAYER, 2021
TABLE 59. UNITED STATES THROMBOSIS DRUG MARKET MERGER & ACQUISITION
TABLE 60. UNITED STATES THROMBOSIS DRUG MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 61. UNITED STATES THROMBOSIS DRUG MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 62. UNITED STATES THROMBOSIS DRUG MARKET INVESTMENT & FUNDING
TABLE 63. UNITED STATES THROMBOSIS DRUG MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 64. UNITED STATES THROMBOSIS DRUG MARKET: LICENSE & PRICING

Companies Mentioned

  • Aspen Pharmacare Holdings Limited
  • AstraZeneca PLC
  • AuroMedics Pharma LLC
  • Baxter International, Inc.
  • Bayer AG
  • Biogen Inc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • DAIICHI SANKYO COMPANY, LIMITED.
  • GlaxoSmithKline plc
  • GoodRx, Inc.
  • Grifols, S.A
  • Inari Medical, Inc.
  • ITALFARMACO S.p.A
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Mylan N.V.
  • Pfizer, Inc
  • Sanofi
  • Vasudha Pharma

Methodology

Loading
LOADING...